|
ES2949648T3
(es)
|
2012-12-20 |
2023-10-02 |
Purdue Research Foundation |
Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
|
|
WO2014130635A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
|
|
US9657105B2
(en)
|
2013-03-15 |
2017-05-23 |
City Of Hope |
CD123-specific chimeric antigen receptor redirected T cells and methods of their use
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
EP3783098A1
(en)
|
2013-05-14 |
2021-02-24 |
Board Of Regents, The University Of Texas System |
Human application of engineered chimeric antigen receptor (car) t-cells
|
|
SG11201509609SA
(en)
|
2013-05-24 |
2015-12-30 |
Univ Texas |
Chimeric antigen receptor-targeting monoclonal antibodies
|
|
WO2015010096A1
(en)
|
2013-07-18 |
2015-01-22 |
Baylor College Of Medicine |
Method of enhancing potency of immune cells
|
|
ES2767423T3
(es)
*
|
2014-01-13 |
2020-06-17 |
Hope City |
Receptores de antígenos quiméricos (CARS) con mutaciones en la región del espaciador Fc y métodos para su uso
|
|
WO2015120187A1
(en)
|
2014-02-05 |
2015-08-13 |
The University Of Chicago |
Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants
|
|
KR102375998B1
(ko)
*
|
2014-02-14 |
2022-03-21 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
키메라 항원 수용체 및 제조방법
|
|
JP6689202B2
(ja)
|
2014-03-19 |
2020-04-28 |
セレクティスＣｅｌｌｅｃｔｉｓ |
癌免疫治療のためのｃｄ１２３特異的キメラ抗原受容体
|
|
PL3888674T3
(pl)
*
|
2014-04-07 |
2024-09-23 |
Novartis Ag |
Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19
|
|
US9212225B1
(en)
|
2014-07-01 |
2015-12-15 |
Amphivena Therapeutics, Inc. |
Bispecific CD33 and CD3 binding proteins
|
|
JP7054622B2
(ja)
|
2014-07-21 |
2022-04-14 |
ノバルティス アーゲー |
ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置
|
|
BR112017000939A2
(pt)
|
2014-07-21 |
2017-11-14 |
Novartis Ag |
tratamento de câncer usando um receptor antigênico quimérico de cll-1
|
|
ES2781175T3
(es)
*
|
2014-07-31 |
2020-08-31 |
Novartis Ag |
Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
|
|
ES2791248T3
(es)
|
2014-08-19 |
2020-11-03 |
Novartis Ag |
Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
|
|
ES2688035T3
(es)
|
2014-08-29 |
2018-10-30 |
Gemoab Monoclonals Gmbh |
Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
|
|
IL292650B2
(en)
*
|
2014-09-19 |
2024-04-01 |
Hope City |
COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2
|
|
EP3215535A2
(en)
*
|
2014-11-05 |
2017-09-13 |
Board of Regents, The University of Texas System |
Gene modified immune effector cells and engineered cells for expansion of immune effector cells
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
HK1245326A1
(zh)
|
2014-12-12 |
2018-08-24 |
Voyager Therapeutics, Inc. |
用於生产scaav的组合物和方法
|
|
CA2974453A1
(en)
|
2015-01-23 |
2016-07-28 |
Sanofi |
Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
|
|
KR102329836B1
(ko)
|
2015-01-26 |
2021-11-19 |
셀렉티스 |
암 면역치료를 위한 항-CLL1 특이적 단일-체인 키메라 항원 수용체들(scCARS)
|
|
JP6912386B2
(ja)
|
2015-01-26 |
2021-08-04 |
ザ ユニバーシティー オブ シカゴ |
癌特異的なＩＬ１３Ｒα２を認識するＣＡＲ Ｔ細胞
|
|
CN107683289B
(zh)
|
2015-01-26 |
2021-08-06 |
芝加哥大学 |
IL13Rα2结合剂和其在癌症治疗中的用途
|
|
US11497767B2
(en)
|
2015-02-18 |
2022-11-15 |
Enlivex Therapeutics R&D Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11596652B2
(en)
|
2015-02-18 |
2023-03-07 |
Enlivex Therapeutics R&D Ltd |
Early apoptotic cells for use in treating sepsis
|
|
IL284985B2
(en)
|
2015-02-18 |
2023-03-01 |
Enlivex Therapeutics R& D Ltd |
Combined immunotherapy and cytokine control therapy for cancer treatment
|
|
US11304976B2
(en)
|
2015-02-18 |
2022-04-19 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11318163B2
(en)
|
2015-02-18 |
2022-05-03 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11000548B2
(en)
|
2015-02-18 |
2021-05-11 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
MX387517B
(es)
*
|
2015-04-06 |
2025-03-18 |
Subdomain Llc |
Polipeptidos que contienen dominios de union de novo y usos de los mismos.
|
|
JP6961490B2
(ja)
|
2015-04-08 |
2021-11-05 |
ノバルティス アーゲー |
Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法
|
|
US10100118B2
(en)
*
|
2015-04-08 |
2018-10-16 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind CD123
|
|
CA2982452A1
(en)
|
2015-04-21 |
2016-10-27 |
Enlivex Therapeutics Ltd. |
Therapeutic pooled blood apoptotic cell preparations and uses thereof
|
|
WO2016180467A1
(en)
|
2015-05-11 |
2016-11-17 |
Biontech Cell & Gene Therapies Gmbh |
Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
|
|
KR102537102B1
(ko)
|
2015-05-29 |
2023-05-25 |
엠피베나 테라퓨틱스, 인크. |
이중특이적 cd33 및 cd3 결합 단백질을 사용하는 방법
|
|
FI3909972T3
(fi)
|
2015-06-19 |
2024-05-03 |
Sebastian Kobold |
Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä
|
|
DK3313874T3
(da)
|
2015-06-26 |
2021-05-03 |
Univ Southern California |
Maskering af kimære antigen-receptor t-celler til tumorspecifik aktivering
|
|
US12115189B2
(en)
|
2015-07-21 |
2024-10-15 |
City Of Hope |
T cells for expression of chimeric antigen receptors and other receptors
|
|
WO2017023138A1
(ko)
*
|
2015-08-05 |
2017-02-09 |
주식회사 유영제약 |
키메라 항원 수용체 및 키메라 항원 수용체가 발현된 t 세포
|
|
EP3569244A1
(en)
*
|
2015-09-23 |
2019-11-20 |
CytoImmune Therapeutics, LLC |
Flt3 directed car cells for immunotherapy
|
|
CA3001230A1
(en)
*
|
2015-10-06 |
2017-04-13 |
City Of Hope |
Chimeric antigen receptors targeted to psca
|
|
CA3001507C
(en)
|
2015-10-16 |
2023-09-19 |
Ludwig-Maximilians-Universitat Munchen |
Cxcr6-transduced t cells for targeted tumor therapy
|
|
CN116712535A
(zh)
|
2015-10-16 |
2023-09-08 |
纽约市哥伦比亚大学理事会 |
用于抑制谱系特异性抗原的组合物和方法
|
|
MX2018004721A
(es)
|
2015-10-23 |
2018-07-06 |
Eureka Therapeutics Inc |
Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
|
|
WO2017075147A1
(en)
|
2015-10-27 |
2017-05-04 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor molecules and uses thereof
|
|
CN108779174B
(zh)
*
|
2015-11-04 |
2022-11-29 |
希望之城公司 |
靶向her2的嵌合抗原受体
|
|
EP4212547A1
(en)
*
|
2015-12-03 |
2023-07-19 |
Juno Therapeutics, Inc. |
Modified chimeric receptors and related compositions and methods
|
|
US11052111B2
(en)
|
2015-12-08 |
2021-07-06 |
Chimera Bioengineering, Inc. |
Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
|
|
CA3009709A1
(en)
|
2015-12-30 |
2017-07-06 |
Novartis Ag |
Immune effector cell therapies with enhanced efficacy
|
|
US11730761B2
(en)
|
2016-02-18 |
2023-08-22 |
Enlivex Therapeutics Rdo Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
WO2017149515A1
(en)
|
2016-03-04 |
2017-09-08 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
KR20230148844A
(ko)
*
|
2016-03-29 |
2023-10-25 |
유니버시티 오브 써던 캘리포니아 |
암을 표적하는 키메라 항원 수용체
|
|
JP7282521B2
(ja)
|
2016-04-08 |
2023-05-29 |
パーデュー・リサーチ・ファウンデイション |
Ｃａｒ ｔ細胞療法のための方法および組成物
|
|
EP3443096B1
(en)
|
2016-04-15 |
2023-03-01 |
Novartis AG |
Compositions and methods for selective expression of chimeric antigen receptors
|
|
WO2017192536A1
(en)
|
2016-05-02 |
2017-11-09 |
University Of Kansas |
Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
|
|
CN109476749A
(zh)
|
2016-06-30 |
2019-03-15 |
豪夫迈·罗氏有限公司 |
改良的过继性t细胞疗法
|
|
KR20190036551A
(ko)
|
2016-08-01 |
2019-04-04 |
노파르티스 아게 |
Pro-m2 대식세포 분자의 억제제를 병용하는, 키메라 항원 수용체를 이용한 암의 치료
|
|
CN107793481A
(zh)
*
|
2016-08-31 |
2018-03-13 |
南京传奇生物科技有限公司 |
一种靶向人cd123的嵌合受体配体及其应用
|
|
CN107840889A
(zh)
*
|
2016-09-19 |
2018-03-27 |
上海吉倍生物技术有限公司 |
高亲和力的抗cd123抗体及其应用
|
|
PL3532497T3
(pl)
|
2016-10-26 |
2024-11-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Zmodyfikowane regiony zawiasowe immunoglobuliny dla zmniejszania hemaglutynacji
|
|
IL266506B2
(en)
*
|
2016-11-16 |
2025-05-01 |
Ablynx Nv |
T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
|
|
WO2018102761A1
(en)
|
2016-12-02 |
2018-06-07 |
City Of Hope |
Methods for manufacturing and expanding t cells expressing chimeric antigen receptors and other receptors
|
|
US11535662B2
(en)
|
2017-01-26 |
2022-12-27 |
Novartis Ag |
CD28 compositions and methods for chimeric antigen receptor therapy
|
|
CN110612119B
(zh)
|
2017-02-07 |
2024-10-29 |
西雅图儿童医院（Dba西雅图儿童研究所） |
磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
|
|
US11850262B2
(en)
|
2017-02-28 |
2023-12-26 |
Purdue Research Foundation |
Compositions and methods for CAR T cell therapy
|
|
US20200048371A1
(en)
*
|
2017-03-31 |
2020-02-13 |
Zymeworks Inc. |
Tumor antigen presentation inducer constructs and uses thereof
|
|
CN110753555A
(zh)
|
2017-04-19 |
2020-02-04 |
得克萨斯州大学系统董事会 |
表达工程化抗原受体的免疫细胞
|
|
AU2018258045B2
(en)
|
2017-04-26 |
2024-02-29 |
Eureka Therapeutics, Inc. |
Chimeric antibody/T-cell receptor constructs and uses thereof
|
|
TWI832818B
(zh)
*
|
2017-07-07 |
2024-02-21 |
南韓商韓美藥品股份有限公司 |
新穎的治療性酵素融合蛋白及其用途
|
|
CA3076337A1
(en)
|
2017-09-19 |
2019-03-28 |
Massachusetts Institute Of Technology |
Compositions for chimeric antigen receptor t cell therapy and uses thereof
|
|
KR20200086278A
(ko)
|
2017-10-18 |
2020-07-16 |
노파르티스 아게 |
선택적 단백질 분해를 위한 조성물 및 방법
|
|
CN107759700A
(zh)
*
|
2017-10-18 |
2018-03-06 |
银丰生物工程集团有限公司 |
靶向cd19抗原的转基因t细胞及其制备方法与应用
|
|
CN111566124A
(zh)
*
|
2017-10-25 |
2020-08-21 |
诺华股份有限公司 |
制备表达嵌合抗原受体的细胞的方法
|
|
KR20200085780A
(ko)
*
|
2017-11-07 |
2020-07-15 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
암의 치료에서 car-t 또는 car-nk 세포를 사용한 lilrb4 표적화
|
|
CA3082410A1
(en)
|
2017-11-14 |
2019-05-23 |
Arcellx, Inc. |
Multifunctional immune cell therapies
|
|
EA202091198A1
(ru)
|
2017-11-14 |
2020-09-09 |
Эрселлкс, Инк. |
Полипептиды, содержащие домен d, и их применение
|
|
US11464803B2
(en)
|
2017-11-14 |
2022-10-11 |
Arcellx, Inc. |
D-domain containing polypeptides and uses thereof
|
|
EP3714041A1
(en)
|
2017-11-22 |
2020-09-30 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
|
GB201719646D0
(en)
*
|
2017-11-27 |
2018-01-10 |
Bivictrix Therapeutics Ltd |
Therapy
|
|
BR112020014913A2
(pt)
|
2018-01-22 |
2020-12-08 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Métodos para uso de células t car
|
|
CN108276495B
(zh)
*
|
2018-01-24 |
2022-03-18 |
博生吉医药科技(苏州)有限公司 |
靶向csf1r嵌合抗原受体修饰的nk92mi细胞和t细胞及其制法和应用
|
|
SG11202007426XA
(en)
|
2018-02-06 |
2020-09-29 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
|
|
CN111918661A
(zh)
|
2018-02-21 |
2020-11-10 |
得克萨斯大学体系董事会 |
用于活化和扩增自然杀伤细胞的方法及其用途
|
|
CA3091674A1
(en)
|
2018-02-23 |
2019-08-29 |
Endocyte, Inc. |
Sequencing method for car t cell therapy
|
|
CN111918877A
(zh)
|
2018-03-14 |
2020-11-10 |
美国卫生和人力服务部 |
抗cd33嵌合抗原受体及其用途
|
|
US12090170B2
(en)
|
2018-04-06 |
2024-09-17 |
The Regents Of The University Of California |
Methods of treating glioblastomas
|
|
WO2019195583A1
(en)
*
|
2018-04-06 |
2019-10-10 |
Mustang Bio, Inc. |
Manufacturing methods for cell-based therapeutic compositions
|
|
EP3773632A4
(en)
|
2018-04-06 |
2022-05-18 |
The Regents of The University of California |
Methods of treating egfrviii expressing glioblastomas
|
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
US20210396739A1
(en)
|
2018-05-01 |
2021-12-23 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
US20210213063A1
(en)
|
2018-05-25 |
2021-07-15 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
WO2019237035A1
(en)
|
2018-06-08 |
2019-12-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
|
TWI890660B
(zh)
|
2018-06-13 |
2025-07-21 |
瑞士商諾華公司 |
Bcma 嵌合抗原受體及其用途
|
|
EP3817767A1
(en)
*
|
2018-07-02 |
2021-05-12 |
Cellectis |
Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
CA3105816A1
(en)
|
2018-07-10 |
2020-01-16 |
Precigen, Inc. |
Ror-1 specific chimeric antigen receptors and uses thereof
|
|
CA3113618A1
(en)
|
2018-09-28 |
2020-04-02 |
Massachusetts Institute Of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
EP3873500A4
(en)
|
2018-10-31 |
2023-01-11 |
Mayo Foundation for Medical Education and Research |
METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
|
|
EP3873540A4
(en)
|
2018-10-31 |
2022-07-27 |
Mayo Foundation for Medical Education and Research |
METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
|
|
US20200222462A1
(en)
*
|
2018-11-30 |
2020-07-16 |
Mustang Bio, Inc. |
Methods of treatment using decitabine and a cd123-targeted therapy
|
|
KR20210106437A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
|
|
AU2020222345B2
(en)
|
2019-02-15 |
2022-11-17 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US12479817B2
(en)
|
2019-02-15 |
2025-11-25 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
BR112021016875A2
(pt)
|
2019-03-01 |
2022-01-04 |
Iovance Biotherapeutics Inc |
Processo para expansão de linfócitos de sangue periférico
|
|
EP3935151A1
(en)
|
2019-03-08 |
2022-01-12 |
Klinikum der Universität München |
Ccr8 expressing lymphocytes for targeted tumor therapy
|
|
WO2020205751A1
(en)
|
2019-03-29 |
2020-10-08 |
City Of Hope |
Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
|
|
WO2020219742A1
(en)
|
2019-04-24 |
2020-10-29 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
EP3990491A1
(en)
|
2019-06-26 |
2022-05-04 |
Massachusetts Institute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
EP3769816A1
(en)
*
|
2019-07-25 |
2021-01-27 |
Ospedale Pediatrico Bambino Gesù |
Car-cd123 vector and uses thereof
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
CN110904048A
(zh)
*
|
2019-12-04 |
2020-03-24 |
合肥中科干细胞再生医学有限公司 |
一种car-cd123t2嵌合抗原受体t细胞及其应用
|
|
CA3161103A1
(en)
*
|
2019-12-16 |
2021-06-24 |
Carl Deselm |
Chimeric antigen receptor dendritic cells (car-dcs) and methods of making and using same
|
|
JP2023506958A
(ja)
|
2019-12-20 |
2023-02-20 |
ノバルティス アーゲー |
骨髄線維症および骨髄異形成症候群を処置するための、デシタビンまたは抗ｐｄ－１抗体スパルタリズマブを伴うかまたは伴わない抗ｔｉｍ－３抗体ｍｂｇ４５３および抗ｔｇｆ－ベータ抗体ｎｉｓ７９３の組合せ
|
|
JP2023517889A
(ja)
|
2020-03-10 |
2023-04-27 |
マサチューセッツ インスティテュート オブ テクノロジー |
ＮＰＭ１ｃ陽性がんの免疫療法のための組成物および方法
|
|
IL296242A
(en)
|
2020-03-10 |
2022-11-01 |
Massachusetts Inst Technology |
Methods for producing engineered memory-like nk cells and preparations containing them
|
|
CN113493772B
(zh)
*
|
2020-04-08 |
2022-10-18 |
华中农业大学 |
可分泌性表达免疫毒素的嵌合抗原受体修饰的免疫细胞
|
|
US12264190B2
(en)
*
|
2020-04-24 |
2025-04-01 |
Astrazeneca Ab |
Compositions and methods of treating cancer with chimeric antigen receptors
|
|
WO2021221782A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
AU2021288224A1
(en)
|
2020-06-11 |
2023-01-05 |
Novartis Ag |
ZBTB32 inhibitors and uses thereof
|
|
WO2021260528A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
WO2022029573A1
(en)
|
2020-08-03 |
2022-02-10 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CN112079927B
(zh)
*
|
2020-09-18 |
2021-12-28 |
西安桑尼赛尔生物医药有限公司 |
一种cd123结合蛋白、含其的car及其应用
|
|
CN112521505B
(zh)
*
|
2020-12-11 |
2022-07-29 |
华道(上海)生物医药有限公司 |
抗cd123抗体及其应用
|
|
CN112646033B
(zh)
*
|
2020-12-16 |
2022-04-12 |
北京艺妙神州医药科技有限公司 |
靶向cd123的嵌合抗原受体及其用途
|
|
WO2022133169A1
(en)
|
2020-12-18 |
2022-06-23 |
Century Therapeutics, Inc. |
Chimeric antigen receptor systems with adaptable receptor specificity
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
WO2023021113A1
(en)
|
2021-08-18 |
2023-02-23 |
Julius-Maximilians-Universität Würzburg |
Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)
|
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
US20250064853A1
(en)
|
2022-01-05 |
2025-02-27 |
Gyala Therapeutics Sociedad Limitada |
Anti-cd84 antibodies and chimeric antigen receptors
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
WO2024094004A1
(zh)
*
|
2022-11-03 |
2024-05-10 |
重庆精准生物技术有限公司 |
靶向cd123的全人源抗体及其应用
|
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
WO2024123835A1
(en)
|
2022-12-06 |
2024-06-13 |
Dynamic Cell Therapies, Inc. |
Engineered switches for immune cell activity and methods of use thereof
|
|
EP4630043A1
(en)
|
2022-12-06 |
2025-10-15 |
Dynamic Cell Therapies, Inc. |
Immune-activating complexes
|
|
AU2024276994A1
(en)
|
2023-05-24 |
2025-10-23 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
CN117430721B
(zh)
*
|
2023-10-25 |
2024-06-25 |
北京景达生物科技有限公司 |
Cd123靶向car-nk细胞的制备及其应用
|
|
EP4599843A1
(en)
|
2024-02-09 |
2025-08-13 |
Fundació Institut de recerca de l'Hospital de la Santa Creu i Sant Pau |
Car and modified cd200r combination
|
|
WO2025255266A1
(en)
|
2024-06-05 |
2025-12-11 |
Dynamic Cell Therapies, Inc. |
Engineered polypeptides for immune cell activation
|